164 related articles for article (PubMed ID: 23614635)
1. Safety concerns with the long-term management of osteoporosis.
Reginster JY; Pelousse F; Bruyère O
Expert Opin Drug Saf; 2013 Jul; 12(4):507-22. PubMed ID: 23614635
[TBL] [Abstract][Full Text] [Related]
2. Prevention of osteoporosis: one step forward, two steps back.
Stevenson JC
Menopause Int; 2011 Dec; 17(4):137-41. PubMed ID: 22120943
[TBL] [Abstract][Full Text] [Related]
3. EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis.
Palacios S; Brincat M; Erel CT; Gambacciani M; Lambrinoudaki I; Moen MH; Schenck-Gustafsson K; Tremollieres F; Vujovic S; Rees M; Rozenberg S
Maturitas; 2012 Feb; 71(2):194-8. PubMed ID: 22176952
[TBL] [Abstract][Full Text] [Related]
4. [Osteoporosis].
Buck G; Perger L; Bischoff-Ferrari HA
Praxis (Bern 1994); 2011 Jul; 100(14):821-32. PubMed ID: 21732293
[No Abstract] [Full Text] [Related]
5. Current options for the management of postmenopausal osteoporosis.
Lecart MP; Reginster JY
Expert Opin Pharmacother; 2011 Nov; 12(16):2533-52. PubMed ID: 21916810
[TBL] [Abstract][Full Text] [Related]
6. The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women.
Komm BS; Morgenstern D; A Yamamoto L; Jenkins SN
Expert Rev Clin Pharmacol; 2015; 8(6):769-84. PubMed ID: 26482902
[TBL] [Abstract][Full Text] [Related]
7. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
Josse R; Khan A; Ngui D; Shapiro M
Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
9. New developments in the treatment of osteoporosis.
Eriksen EF; Halse J; Moen MH
Acta Obstet Gynecol Scand; 2013 Jun; 92(6):620-36. PubMed ID: 22646526
[TBL] [Abstract][Full Text] [Related]
10. Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.
Cole RE
Postgrad Med; 2011 Mar; 123(2):131-44. PubMed ID: 21474901
[TBL] [Abstract][Full Text] [Related]
11. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.
Lewiecki EM
J Womens Health (Larchmt); 2009 Oct; 18(10):1615-26. PubMed ID: 19857095
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapies to manage bone loss-associated diseases: a quest for the perfect benefit-to-risk ratio.
Valverde P
Curr Med Chem; 2008; 15(3):284-304. PubMed ID: 18288984
[TBL] [Abstract][Full Text] [Related]
13. Drugs for postmenopausal osteoporosis.
Treat Guidel Med Lett; 2008 Oct; 6(74):67-74; quiz 75-6. PubMed ID: 18800025
[No Abstract] [Full Text] [Related]
14. Individualizing osteoporosis therapy.
Silverman S; Christiansen C
Osteoporos Int; 2012 Mar; 23(3):797-809. PubMed ID: 22218417
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of currently marketed anti-osteoporosis medications.
Reginster JY; Neuprez A; Dardenne N; Beaudart C; Emonts P; Bruyere O
Best Pract Res Clin Endocrinol Metab; 2014 Dec; 28(6):809-34. PubMed ID: 25432354
[TBL] [Abstract][Full Text] [Related]
16. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis.
Neuprez A; Hiligsmann M; Scholtissen S; Bruyere O; Reginster JY
Adv Ther; 2008 Dec; 25(12):1235-56. PubMed ID: 19066755
[TBL] [Abstract][Full Text] [Related]
17. Safety issues and adverse reactions with osteoporosis management.
Rossini M; Adami G; Adami S; Viapiana O; Gatti D
Expert Opin Drug Saf; 2016; 15(3):321-32. PubMed ID: 26699669
[TBL] [Abstract][Full Text] [Related]
18. Drug-Related Adverse Events of Osteoporosis Therapy.
Khan M; Cheung AM; Khan AA
Endocrinol Metab Clin North Am; 2017 Mar; 46(1):181-192. PubMed ID: 28131131
[TBL] [Abstract][Full Text] [Related]
19. [Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium].
Uebelhart D; Frey D; Frey-Rindova P; Goerres G; Michel BA
Z Rheumatol; 2003 Dec; 62(6):512-7. PubMed ID: 14685711
[TBL] [Abstract][Full Text] [Related]
20. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
